Investors like what they heard from GW Pharma at epilepsy meeting

Shares of GW Pharmaceuticals (GWPH +11.9%) pop on a 2x surge in volume in early trading. Investors seem to like what they heard during the company's Epidiolex presentation at the Dravet Syndrome conference this past weekend. Several weeks ago, the company reported preliminary results from a clinical trial demonstrating a significant reduction in seizures in the the Epidiolex-treated cohort.

Epiolex is designated an Orphan Drug for Dravet and Lennox-Gastaut syndromes.

Recently, the FDA designated another cannabadiol product from Insys Therapeutics (INSY +1.6%) an Orphan Drug for the treatment of Lennox-Gastaut syndrome.

From other sites
Comments (7)
  • Obee1
    , contributor
    Comments (34) | Send Message
    I would like to hear someone address the fact that CEO's dumped shares, and a 60% stake, $43 million of a company with Zero Revenue. If GWPH is such a gem, why would the CEO's let go of so many shares?
    30 Jun 2014, 01:13 PM Reply Like
  • Doyee51986
    , contributor
    Comments (330) | Send Message
    Would you care to elaborate?



    There is no reduction in stake here...


    Likely the CEO also was long from the beginning, and the stocks ran up from 9 dollars to 108 dollars. He may have wanted to sell stock to realize longterm gains if you are correct.


    The company is meeting an unmet need for treating Epilepsy with a drug superior to that of Insys. That is why this is a gem.
    30 Jun 2014, 07:04 PM Reply Like
  • Obee1
    , contributor
    Comments (34) | Send Message
    I understand taking profits, but 60% is a ridiculous amount of shares to dump as a CEO, especially if the company is so amazing.. Raises a red flag for me, I also find it troubling that Cramer won't even touch on the subject.


    There are other bio-techs coming out with generic versions of what GWPH has, also, why not just use the natural CBD oil as opposed to paying the big dollars for a patented pharmaceutical?


    I haven't drank the kool-aid fully on this one yet. The CEO dumping 60% of his holdings when this is supposedly so amazing is a bit questionable for me. You, also have to admit that the valuation for this company is just ridiculous?
    30 Jun 2014, 08:03 PM Reply Like
  • Doyee51986
    , contributor
    Comments (330) | Send Message
    No, I don't admit the evaluation of this company is just ridiculous because Morgan Stanley said a more liberal price target was 240 a share, and a conservative price target is 105. It's undervalued until its 240 - just ask Morgan Stanley. The stocks up today based on another price target 50% above the current price.


    They are doing it because shares are UNDER not overvalued.
    1 Jul 2014, 11:33 AM Reply Like
  • Obee1
    , contributor
    Comments (34) | Send Message
    page s-359 in the prospectus:


    - CEO Gover selling 40% stake
    - CSO Wright selling 2/3 stake


    Those are huge numbers if your company is such a gem, doesn't give me the feeling of confidence.


    INSY will have synthetic versions of what GWPH has, and why not use the 100% CBD straight from the plant, as opposed to paying top dollar for patented drugs?


    I think GWPH has two things going for it; 1. It is the first company in the race. 2. Cramer pumps it and pumps it.


    I think many other companies with much more rational valuations are on their way..
    30 Jun 2014, 08:17 PM Reply Like
  • Withermania
    , contributor
    Comments (54) | Send Message
    GWPH does have more than what you mention going for it. Cannibidiol is recognized to have many anti tumor properties specifically within the neck and head area. This is known within the medical field. GWPH is a pure play on this therapy which has potentially many uses. Epilepsy is just the beginning. The results are very impressive and the fact is it's SAFE. There are no other good treatments. In regards to the CEO and CSO selling shares, they are taking profits and will be awarded new shares as the company grows. Plus GWPH does 50 million revs and already has a drug "savitix" on the market in 20 countries. Perception will drive this stock to $150. Huge takeout potential. GET LONG
    30 Jun 2014, 10:00 PM Reply Like
  • Rumpel Pumpel
    , contributor
    Comments (431) | Send Message
    60%?? Gover offers about 3mio of his shares , which equals about 8% sell of his over 18mio shares. Look table below, where do you get those numbers from?


    Named Executive Officers and Directors


    Dr. Geoffrey Guy(5) holding 18,711,986 shares before the offering and sells 8.6% or 3,112,428 shares. 15,599,558 shares left.
    1 Jul 2014, 08:41 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs